JP2018504584A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504584A5 JP2018504584A5 JP2017529256A JP2017529256A JP2018504584A5 JP 2018504584 A5 JP2018504584 A5 JP 2018504584A5 JP 2017529256 A JP2017529256 A JP 2017529256A JP 2017529256 A JP2017529256 A JP 2017529256A JP 2018504584 A5 JP2018504584 A5 JP 2018504584A5
- Authority
- JP
- Japan
- Prior art keywords
- integrin
- subject
- level
- predictive marker
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 50
- 108010044426 integrins Proteins 0.000 claims 36
- 102000006495 integrins Human genes 0.000 claims 36
- 239000003550 marker Substances 0.000 claims 22
- 229940079593 drug Drugs 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 21
- 238000011282 treatment Methods 0.000 claims 21
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 13
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims 12
- 102000055025 Adenosine deaminases Human genes 0.000 claims 12
- 102000009088 Angiopoietin-1 Human genes 0.000 claims 12
- 108010048154 Angiopoietin-1 Proteins 0.000 claims 12
- 102000008100 Human Serum Albumin Human genes 0.000 claims 12
- 108091006905 Human Serum Albumin Proteins 0.000 claims 12
- 210000002966 serum Anatomy 0.000 claims 12
- 102000009075 Angiopoietin-2 Human genes 0.000 claims 11
- 108010048036 Angiopoietin-2 Proteins 0.000 claims 11
- 108010074051 C-Reactive Protein Proteins 0.000 claims 11
- 102100032752 C-reactive protein Human genes 0.000 claims 11
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 claims 11
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 11
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 10
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 8
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 8
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 claims 8
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 claims 8
- 230000004044 response Effects 0.000 claims 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 7
- 238000003556 assay Methods 0.000 claims 6
- 238000001514 detection method Methods 0.000 claims 6
- 230000009977 dual effect Effects 0.000 claims 6
- 238000003018 immunoassay Methods 0.000 claims 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 108010008165 Etanercept Proteins 0.000 claims 4
- 102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 claims 4
- 101710139349 Mucosal addressin cell adhesion molecule 1 Proteins 0.000 claims 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 4
- 229940104788 entyvio Drugs 0.000 claims 4
- 238000007619 statistical method Methods 0.000 claims 4
- 229960004914 vedolizumab Drugs 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 238000009115 maintenance therapy Methods 0.000 claims 3
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 2
- 229960002964 adalimumab Drugs 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 229940090100 cimzia Drugs 0.000 claims 2
- 229940073621 enbrel Drugs 0.000 claims 2
- 229960000403 etanercept Drugs 0.000 claims 2
- 238000009093 first-line therapy Methods 0.000 claims 2
- 229960001743 golimumab Drugs 0.000 claims 2
- 229940048921 humira Drugs 0.000 claims 2
- 238000011419 induction treatment Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 229960000598 infliximab Drugs 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 229940116176 remicade Drugs 0.000 claims 2
- 229940068638 simponi Drugs 0.000 claims 2
- 229940071598 stelara Drugs 0.000 claims 2
- 229960003824 ustekinumab Drugs 0.000 claims 2
- 238000011418 maintenance treatment Methods 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086549P | 2014-12-02 | 2014-12-02 | |
| US62/086,549 | 2014-12-02 | ||
| US201562157903P | 2015-05-06 | 2015-05-06 | |
| US62/157,903 | 2015-05-06 | ||
| PCT/IB2015/059303 WO2016088068A1 (en) | 2014-12-02 | 2015-12-02 | Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018504584A JP2018504584A (ja) | 2018-02-15 |
| JP2018504584A5 true JP2018504584A5 (enExample) | 2019-01-17 |
Family
ID=54849673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529256A Pending JP2018504584A (ja) | 2014-12-02 | 2015-12-02 | 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10324088B2 (enExample) |
| EP (1) | EP3227685A1 (enExample) |
| JP (1) | JP2018504584A (enExample) |
| CA (1) | CA2969326A1 (enExample) |
| HK (1) | HK1244881A1 (enExample) |
| MX (1) | MX2017006959A (enExample) |
| WO (1) | WO2016088068A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018349287A1 (en) * | 2017-10-10 | 2020-05-07 | Prometheus Biosciences, Inc. | Methods for monitoring vedolizumab treatment |
| EP3765634A4 (en) | 2018-03-16 | 2021-12-01 | Scipher Medicine Corporation | METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE TO ANTI-TNF THERAPIES |
| EP3543692A1 (en) * | 2018-03-22 | 2019-09-25 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Adhesion assay |
| WO2020226498A1 (en) | 2019-05-07 | 2020-11-12 | Rijksuniversiteit Groningen | Biomarker, kit and method for predicting clinical responsiveness to therapy with an agent that targets alpha4beta7 integrin. |
| GB2603294A (en) | 2019-06-27 | 2022-08-03 | Scipher Medicine Corp | Developing classifiers for stratifying patients |
| TW202504919A (zh) | 2023-05-30 | 2025-02-01 | 美商派拉岡醫療公司 | α4β7整合素抗體組合物及使用方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830675A (en) | 1993-03-10 | 1998-11-03 | Cedars-Sinai Medical Center | Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis |
| DE69424700T2 (de) | 1993-03-10 | 2000-11-09 | Cedars-Sinai Medical Center, Los Angeles | Verfahren zum selektiven Nachweis von perinuklearen anti-neutrophilen cytoplasmischen Antikörpern bei ulzerativen Kolitis oder primärer sclerotischer Cholangitis |
| US6218129B1 (en) | 1998-05-15 | 2001-04-17 | Prometheus Laboratories, Inc. | Inflammatory bowel disease first step assay system |
| US6406862B1 (en) | 1998-10-06 | 2002-06-18 | The United States Of America As Represented By The Secretary Of The Army | Dip-stick assay for C-reactive protein |
| US6838250B2 (en) | 2000-03-31 | 2005-01-04 | Ortho-Clinical Diagnostics, Inc. | Immunoassay for C-reactive protein |
| WO2005041896A2 (en) | 2003-11-03 | 2005-05-12 | Duke University | Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke |
| US20060019410A1 (en) | 2004-07-21 | 2006-01-26 | Qualyst, Inc. | Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation |
| US7873479B2 (en) | 2005-12-01 | 2011-01-18 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
| US20090035216A1 (en) * | 2007-08-03 | 2009-02-05 | Biomonitor Aps | Method for determining in vivo biopharmaceutical concentration or bioavailability |
| NZ600339A (en) | 2008-02-25 | 2013-12-20 | Nestec Sa | Drug selection for breast cancer therapy using antibody-based arrays |
| CN102124344B (zh) * | 2008-05-16 | 2015-04-01 | 霍夫曼-拉罗奇有限公司 | 生物标记用于评估β7整联蛋白拮抗剂治疗胃肠道炎性病症的用途 |
| WO2010144358A1 (en) | 2009-06-08 | 2010-12-16 | Singulex, Inc. | Highly sensitive biomarker panels |
| NZ621655A (en) | 2009-10-26 | 2015-08-28 | Nestec Sa | Assays for the detection of anti-tnf drugs and autoantibodies |
| HRP20241666T1 (hr) * | 2010-10-25 | 2025-02-14 | Biogen Ma Inc. | Metode za određivanje razlika u alfa-4 integrinskoj aktivnosti pomoću korelacijskih razlika u razinama svcam i/ili smadcam |
| CA2839792A1 (en) * | 2011-05-10 | 2012-11-15 | Nestec S.A. | Methods of disease activity profiling for personalized therapy management |
| JP2015502740A (ja) * | 2011-10-21 | 2015-01-29 | ネステク ソシエテ アノニム | 炎症性腸疾患の診断を改善するための方法 |
| US20140051184A1 (en) | 2012-08-15 | 2014-02-20 | Nestec S.A. | Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto |
| RU2015112024A (ru) * | 2012-10-05 | 2016-11-27 | Дженентек, Инк. | Способы диагностики и лечения воспалительного заболевания кишечника |
| CN105143876B (zh) * | 2013-03-27 | 2018-04-20 | 豪夫迈·罗氏有限公司 | 生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途 |
| CA2912993A1 (en) * | 2013-05-24 | 2014-11-27 | Nestec S.A. | Pathway specific markers for diagnosing irritable bowel syndrome |
-
2015
- 2015-12-02 WO PCT/IB2015/059303 patent/WO2016088068A1/en not_active Ceased
- 2015-12-02 CA CA2969326A patent/CA2969326A1/en not_active Abandoned
- 2015-12-02 MX MX2017006959A patent/MX2017006959A/es unknown
- 2015-12-02 JP JP2017529256A patent/JP2018504584A/ja active Pending
- 2015-12-02 EP EP15808468.1A patent/EP3227685A1/en not_active Withdrawn
- 2015-12-02 HK HK18104344.5A patent/HK1244881A1/zh unknown
-
2017
- 2017-05-22 US US15/601,921 patent/US10324088B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504584A5 (enExample) | ||
| Mason et al. | HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant | |
| Mederacke et al. | Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay | |
| Lidar et al. | Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true pathogenic role | |
| Robinson et al. | Biomarkers to guide clinical therapeutics in rheumatology? | |
| Kearney et al. | The building blocks of successful translation of proteomics to the clinic | |
| Alturaiki et al. | Assessment of IL‐1β, IL‐6, TNF‐α, IL‐8, and CCL 5 levels in newly diagnosed Saudi patients with rheumatoid arthritis | |
| JP2014531584A5 (enExample) | ||
| JP2016536002A (ja) | 抗ｔｌ１ａ療法のためのシステム、デバイス、及び方法 | |
| TW201842191A (zh) | 預測患有發炎性腸病之個體對抗-tnf治療無反應的方法 | |
| JP2015514227A5 (enExample) | ||
| Ostrowski et al. | Common functional alterations identified in blood transcriptome of autoimmune cholestatic liver and inflammatory bowel diseases | |
| Van Der Leest et al. | Critical factors in the analytical work flow of circulating tumor DNA-based molecular profiling | |
| WO2008048986A3 (en) | Gene array technique for predicting response in inflammatory bowel diseases | |
| Assis et al. | A macrophage migration inhibitory factor polymorphism is associated with autoimmune hepatitis severity in US and Japanese patients | |
| Bexfield et al. | Canine hepacivirus is not associated with chronic liver disease in dogs | |
| Ng et al. | Unmet needs in psoriatic arthritis | |
| Alsoud et al. | Best practice for therapeutic drug monitoring of infliximab: position statement from the international association of therapeutic drug monitoring and clinical toxicology | |
| Lamoury et al. | Evaluation of a hepatitis C virus core antigen assay in plasma and dried blood spot samples | |
| Shen et al. | Expansion of macrophage and liver sinusoidal endothelial cell subpopulations during non-alcoholic steatohepatitis progression | |
| Nam et al. | Clinical performance evaluation of the BD Veritor System Flu A+ B assay | |
| Xu et al. | Epstein-Barr virus infection in ulcerative colitis: a clinicopathologic study from a Chinese area | |
| Chen et al. | Femtomolar SARS-CoV-2 antigen detection using the microbubbling digital assay with smartphone readout enables antigen burden quantitation and tracking | |
| Lanzillo et al. | JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level | |
| Balta et al. | Neutrophil-to-lymphocyte ratio may predict subclinical atherosclerosis in patients with psoriasis. |